Page last updated: 2024-11-13
cep 8983
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CEP 8983: inhibits PAR polymerase-1 and PAR polymerase-2; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23584940 |
| SCHEMBL ID | 3361947 |
| MeSH ID | M0514396 |
Synonyms (16)
| Synonym |
|---|
| cep-8983 |
| cep 8983 |
| cep8983 |
| 917828-47-8 |
| 374071-46-2 |
| 1h-cyclopenta(a)pyrrolo(3,4-c)carbazole-1,3(2h)-dione, 4,5,6,7-tetrahydro-11-methoxy- |
| unii-e5ya7gmh0h |
| e5ya7gmh0h , |
| SCHEMBL3361947 |
| cep 8983 [who-dd] |
| DTXSID10190845 |
| 14-methoxy-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione |
| Q27276911 |
| 11-methoxy-4,5,6,7-tetrahydro-1h-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2h)-dione |
| PD163104 |
| AKOS040748104 |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Twenty-six patients received CEP-9722 150-1,000 mg/day combined with temozolomide." | ( Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||